Assessing direct costs of treating metastatic triple-negative breast cancer in the USA

Skinner, Karen E; Haiderali, Amin; Huang, Min; Schwartzberg, Lee S.

doi:10.2217/cer-2020-0213

Cited by 8 publications

(14 citation statements)

References 15 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, it was found that the total cost from first year to fifth year gradually decreased and most of the costs were incurred by cancer-related health services in mTNBC patients. In addition, hospitalization accounted for a major proportion of medical costs as observed in previous studies 20 , 21 . These findings may reflect the treatment patterns of mTNBC patients.…”

Section: Discussionsupporting

confidence: 62%

“…Once diagnosed, patients usually receive intensive treatments and then are monitored closely during follow-up. Even though average treatment costs increased from first-line therapy to therapies of subsequent lines 9 , 20 , the downward trend of mean total cost may be affected by decreasing number of patients receiving later lines of therapy. The findings of this study further demonstrated that older age was associated with lower medical costs.…”

Section: Discussionmentioning

confidence: 99%

“…Healthcare costs of mTNBC patients have been examined in western countries 9 , 20 , 21 . Of the elderly mTNBC patients in the US, the mean cumulative cost was US$73,586, and mean cost in first-line and second-line treatments was US$26,950 and US$33,347, respectively.…”

Section: Introductionmentioning

confidence: 99%

“…Physician/clinic cost was the highest during pre-treatment, first regimen, second regimen, and third and subsequent regimens phases 9 . Another study also examined costs during different lines of systemic therapy in mTNBC patients in the US and found that the mean total cost increased from US$21,908 in the first-line therapy to US$25,845 in the third-line therapy 20 . Hospitalization costs accounted for almost half of the total cost, followed by the costs of systemic anti-cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer

Hsu

Chang

Cheng

2022

Sci Rep

View full text Add to dashboard Cite

Individuals diagnosed with metastatic triple-negative breast cancer (mTNBC) suffer worse survival rates than their metastatic non-TNBC counterparts. There is little information on survival, treatment patterns, and medical costs of mTNBC patients in Asia. Therefore, this study aimed to examine 5-year survival, regimens of first-line systemic therapy, and healthcare costs of mTNBC patients in Taiwan. Adult females newly diagnosed with TNBC and non-TNBC as well as their survival data, treatment regimens and costs of health services were identified and retrieved from the Cancer Registry database, Death Registry database, and National Health Insurance (NHI) claims database. A total of 9691 (19.27%) women were identified as TNBC among overall BC. The 5-year overall survival rate of TNBC and non-TNBC was 81.28% and 86.50%, respectively, and that of mTNBC and metastatic non-TNBC was 10.81% and 33.46%, respectively. The majority of mTNBC patients received combination therapy as their first-line treatment (78.14%). The 5-year total cost in patients with metastatic non-TNBC and with mTNBC was NTD1,808,693 and NTD803,445, respectively. Higher CCI scores were associated with an increased risk of death and lower probability of receiving combination chemotherapy. Older age was associated with lower 5-year medical costs. In sum, mTNBC patients suffered from poorer survival and incurred lower medical costs than their metastatic non-TNBC counterparts. Future research will be needed when there are more treatment options available for mTNBC patients.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer

Hsu

Chang

Cheng

2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Ten studies included in the review assessed both the direct costs and HCRU [35][36][37][38][39][40][41][42][43][44]. Six studies only assessed the direct costs [41,[45][46][47][48][49], while two studies only evaluated HCRU associated with TNBC [50,51]. Two studies assessed both direct and indirect costs of TNBC [45,52], although one study reported indirect costs only [53].…”

Section: Economic Burden Of Triple-negative Breast Cancer (Tnbc)mentioning

confidence: 99%

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Huang

Haiderali

Fox³

et al. 2022

PharmacoEconomics

Self Cite

View full text Add to dashboard Cite

Background Triple-negative breast cancer (TNBC) accounts for 10-20% of all breast cancers (BCs). It is more commonly diagnosed in younger women and often has a less favorable prognosis compared with other BC subtypes.Objective The objective of this study was to provide a literature-based extensive overview of the economic and humanistic burden of TNBC to assist medical decisions for healthcare payers, providers, and patients. Methods A systematic literature review was performed using multiple databases, including EMBASE, MEDLINE, Econlit, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, from database inception to 16 May 2021. In addition, a targeted search was performed in the Northern Light Life Sciences Conference Abstracts database from 2016 through June 2021. The bibliographies of included articles were reviewed to identify other potentially relevant publications. Quality assessment of the included studies was conducted. ResultsThe review identified 19 studies assessing the economic burden and 10 studies assessing the humanistic burden of TNBC. Studies varied widely in study design, settings, patient populations, and time horizons.

show abstract

Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021

et al. 2022

View full text Add to dashboard Cite

ImportanceAdvances in treatment of metastatic breast cancer (MBC) led to changes in clinical practice and treatment costs in the US over the past decade. There is limited information on current MBC treatment sequences and associated costs by MBC subtype in the US.ObjectivesTo identify treatment patterns by MBC subtype and associated anticancer and supportive drug costs from health care sector and Medicare perspectives.Design, Setting, and ParticipantsThis economic evaluation analyzed data of patients with MBC obtained from the nationwide Flatiron Health database, an electronic health record–derived, deidentified database with data from community and academic practices across the US from 2011 to 2021. Participants included women aged at least 18 years diagnosed with MBC, who had at least 6 months of follow-up data, known hormone receptor (HR) and human epidermal growth factor receptor 2 (ERBB2) receptor status, and at least 1 documented line of therapy. Patients with documented receipt of clinical study drugs were excluded. Data were analyzed from June 2021 to May 2022.Main Outcomes and MeasuresOutcomes of interest were frequency of different drug regimens received as a line of therapy by subtype for the first 5 lines and mean medical costs of documented anticancer treatment and supportive care drugs per patient by MBC subtype and years since metastatic diagnosis, indexed to 2021 US dollars.ResultsAmong 15 215 patients (10 171 patients [66.85%] with HR-positive and ERBB2-negative MBC; 2785 patients [18.30%] with HR-positive and ERBB2-positive MBC; 802 patients [5.27%] with HR-negative and ERBB2-positive MBC; 1457 patients [9.58%] with triple-negative breast cancer [TNBC]) who met eligibility criteria, 1777 (11.68%) were African American, 363 (2.39%) were Asian, and 9800 (64.41%) were White; the median (range) age was 64 (21-84) years. The mean total per-patient treatment and supportive care drug cost using publicly available Medicare prices was $334 812 for patients with HR-positive and ERBB2-positive MBC, $284 609 for patients with HR-negative and ERBB2-positive MBC, $104 774 for patients with HR-positive and ERBB2-negative MBC, and $54 355 for patients with TNBC. From 2011 to 2019 (most recent complete year 1 data are for patients diagnosed in 2019), annual costs in year 1 increased from $12 986 to $80 563 for ERBB2-negative and HR-positive MBC, $99 997 to $156 712 for ERBB2-positive and HR-positive MBC, and $31 397 to $53 775 for TNBC.Conclusions and RelevanceThis economic evaluation found that drug costs related to MBC treatment increased between 2011 and 2021 and differed by tumor subtype. These findings suggest the growing financial burden of MBC treatment in the US and highlights the importance of performing more accurate cost-effectiveness analysis of novel adjuvant therapies that aim to reduce metastatic recurrence rates for early-stage breast cancer.

show abstract

Assessing direct costs of treating metastatic triple-negative breast cancer in the USA

Cited by 8 publications

References 15 publications

Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer

Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021

Contact Info

Product

Resources

About